Pliant calls it quits on Phase 2b IPF study
Pliant Therapeutics has officially discontinued a mid-stage study of its chronic lung disease treatment, less than a month after the trial's safety board recommended a halt. The South San Francisco...
View ArticleGSK, Amgen and AstraZeneca tout Phase 3 data in inflammatory nasal condition
GSK, Amgen and AstraZeneca released positive data supporting their rival drugs in a condition called chronic rhinosinusitis with nasal polyps, or CRSwNP. GSK’s depemokimab and Amgen and AstraZeneca’s...
View ArticleCerebral CEO David Mou has stepped down
The CEO of mental health startup Cerebral stepped down in December 2024, Endpoints News has learned. David Mou, who became CEO in May 2022, continues to serve in his previous post of chief medical...
View ArticleSofinnova Partners raises €1.2B to invest in life sciences
Sofinnova Partners has raised €1.2 billion ($1.26 billion) across its various investment strategies over the past year, the European life sciences investor said Tuesday morning, sharing its plans to...
View Article23andMe rejects CEO's second take-private offer
A special committee of 23andMe's board rejected CEO Anne Wojcicki's latest offer to take the company private. In her second attempt, Wojcicki — along with private equity firm New Mountain Capital —...
View ArticleNIH-backed research tries to use stem cells to restore the eye’s outer layer
Thirteen out of 14 people with eye damage experienced at least some improvements to their cornea after receiving a stem cell transplant in one eye in an early-stage study. The National Institutes of...
View ArticleUnitedHealthcare’s copay-only plan is booming, despite backlash over care...
Business is booming for UnitedHealthcare’s transparent-pricing health plan, as more companies consider offering alternative types of health insurance. The plan, called Surest, aims to fix a universal...
View ArticleBourla says Pfizer could transfer production to US to sidestep Trump's tariffs
Pfizer could “quickly” transfer operations from foreign sites to its US manufacturing network as a way to mitigate any impact from President Donald Trump’s tariffs, CEO Albert Bourla said. The pharma...
View ArticleTenaya raises about $53M; BeiGene’s PD-1 gets a first-line approval
Plus, news about Evotec and Osivax: Tenaya Therapeutics’ $52.5M public offering: The heart disease specialist intends to spend the proceeds from its offering of 75 million new shares to develop...
View ArticleAcelyrin rejects buyout offer from Tang’s Concentra, sticks to Alumis merger
The board of immunology biotech Acelyrin has rejected the buyout offer from Tang Capital's shell company Concentra Biosciences, clearing up any doubt about its pending merger with Alumis. Acelyrin's...
View ArticleSwiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and...
A small Swiss biotech has terminated a mid-stage test of a new type of oral drug for people with Alzheimer's disease, according to the federal clinical trials database. About eight months ago,...
View ArticlePepGen delays study for Duchenne drug as it awaits safety data from another...
PepGen is "temporarily pausing" a Phase 2 study of its exon 51 skipping drug for Duchenne muscular dystrophy, it said Tuesday. PepGen told Endpoints News via email that no patients have been enrolled...
View ArticleDOGE shutters lease on FDA lab in St. Louis and 29 other sites
The Department of Government Efficiency says that it has terminated the leases of 30 FDA offices and buildings, including a 52,000 square-foot St. Louis-based lab that operates under the FDA's Office...
View ArticleTeladoc holds out for 2026
Teladoc is in a rebuilding era. Once a stock market darling during the pandemic, the telehealth giant has been forced to reinvent itself. Its forecasted revenue for 2025 is flat ...
View ArticleMisleading promotion lands NJ drugmaker a letter from FDA
Edenbridge Pharmaceuticals received this year's first untitled letter from the FDA's drug promotion office over misleading claims in an advertisement for the company's multiple myeloma drug Hemady. The...
View ArticleChina bans imports of Illumina's DNA sequencers following US tariffs
China will ban the import of DNA sequencers from San Diego-based Illumina, an apparent response to additional US tariffs. Last month, the Chinese government placed Illumina on an "unreliable entities"...
View ArticlePersica shares early data for antibiotic in chronic back pain
Persica Pharmaceuticals said it has promising Phase 1b results that support its approach of using a two-dose antibiotic to treat a subset of patients with chronic back pain. Chronic low back pain in...
View ArticleEli Lilly seeks pitches from US states for slice of $27B manufacturing buildout
Eli Lilly is doing something out of the box to find where it should pour its latest manufacturing commitment. In a company first, the pharma giant is welcoming pitches from US ...
View ArticleBayer cautions pharma sales dip this year despite major upcoming launches
Bayer said Wednesday its pharmaceuticals unit will likely see a decline in sales in 2025, as the company reported another set of lackluster earnings amid its best efforts at a multiyear turnaround. The...
View ArticleJazz to buy Chimerix for $935M to get brain tumor drug five months ahead of...
Jazz Pharmaceuticals will buy North Carolina biotech Chimerix for $935 million in cash, the companies said Wednesday morning. Through the deal, Jazz gets access to a potential first-ever treatment for...
View Article